Please ensure Javascript is enabled for purposes of website accessibility

Vaccine Makers vs. COVID Variants: What Are Their Strategies?

By Morgan McSweeney - Mar 31, 2021 at 6:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Each vaccine maker's approach to tackling new variants differs in slight, but important, ways.

When new coronavirus variants emerged in Brazil, South Africa, and the U.K., vaccine developers wasted little time constructing plans to battle back. Now, companies including Moderna (MRNA 8.73%), Pfizer (PFE -0.15%), Johnson and Johnson (JNJ 0.91%), and AstraZeneca (AZN 1.05%) are working on updated vaccines and specialized boosters.

While they're perfecting new shots, the coronavirus continues to spread, and while it does, the threat of even newer strains emerging remains. This leaves public health experts and the average individual alike wondering: What's each business' expected development timeline for these new protective measures? 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$181.09 (0.91%) $1.63
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.91 (-0.15%) $0.08
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$67.40 (1.05%) $0.70
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$147.66 (8.73%) $11.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.